Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Videos
TRS100 - Quantitative Content Uniformity...
RapID - A Better Way to ID Raw Materials...Virus-inspired DNA Nanodevices...IBM Watson / MSK Collaboration...

Featured Products
Featured Product - Patheon Biologics
Patheon Biologics

Webcasts
Webcasts - High-Throughput Approaches to Cell BiologyHigh-Throughput Approaches to Cell Biology
Robin Ketteler, University College London, speaking at Screening Europe 2015.
Webcasts - Balancing Leverage with Stewardship of a Corporate Compound CollectionBalancing Leverage with Stewardship of a Corporate Compound Collection
Rose Gonzales, Pfizer Global R&D, speaking at Drug Discovery and Development 2014

Market Reports
Immunoassay Auto Trends 2014
HTStec

This report comprehensively documents current practices and preferences in immunoassays and to understand future user requirements, particularly with respect to immunoassay automation.
Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018
MarketsandMarkets

Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications.
Epigenetic Modification Screening Trends 2014
HTStec

This market report summarizes the results of HTStec’s 3nd industry-wide global web-based benchmarking survey on epigenetic modification screening carried out in May 2014.
Multi-Mode Microplate Reader Trends 2013
HTStec

This market report summarizes the results of HTStec’s 4th industry-wide global web-based benchmarking survey on multi-mode microplate readers carried out in September 2013.
GPCR Screening & Profiling Trends 2013
HTSTec

This market report summarizes the results of HTStec’s 5th industry-wide global web-based benchmarking survey on GPCR screening and profiling carried out in August 2013.
China Pharmaceutical Market Outlook
Global Data

The report details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity
GBI Research

The report examines the reasons why the pharmaceutical industry is looking for improvements in efficiency whilst acknowledging that pharmaceutical R&D remains a long and risky process. It looks in detail at precompetitive research and evaluates how the industry is pulling together to research solutions to problems that are common to all companies.
Drug Discovery and Development Market in Asia
Global Data

The report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea.
Biopharmaceutical Manufacturing in India, China and South Korea
GBI Research

The report provides an analysis of biopharmaceuticals approved in 2010 and 2011, operating dynamics in the biopharmaceutical industry, the current scenario in biopharmaceutical manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals, and forecasts to 2016 for India, China, South Korea and the global market.
Outsourced Ion Channel Testing Trends 2013
HTStec

HTStec's Outsourced Ion Channel Testing Trends 2013 report was published on 3 May 2013. This 58 page market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on outsourced ion channel testing carried out in April 2013.
Scientific News
Human Trials of Manufactured Blood Within Two Years
The first human trials of lab-produced blood to help create better-matched blood for patients with complex blood conditions has been announced by NHS Blood and Transplant.
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Behavior Matters: Redesigning the Clinical Trial
A recent meta-analysis of six such clinical trials shows that behavior can have a serious impact on the effectiveness of a treatment and that the currently used DBRCT procedures may not be able to assess the effects of behavior on the treatment.
New Commercial Method for Producing Medical Isotope
The effort to secure a stable, domestic source of a critical medical isotope reached an important milestone this month as scientists demonstrated the production, separation and purification of molybdenum-99 (Mo-99.
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
IAOCR Welcomes Important Initial Step for Regulating European Clinical Trials
New regulation to ensure a more streamlined risk-based approach to the conduct of trials with more public openness about each trial and the results they produce.
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Amgen Terminates Co-Development of Brodalumab with AstraZeneca
This move follows the release of clinical trial data which suggests the experimental drug has severe side effects.
Baylor, TGen Collaborate on Personalized Cancer Treatment Options
The companies will collaborate on precision medicine for cancer patients by offering liquid biopsies, performing gene sequencing, conducting clinical trials, and creating personalized vaccines.
Business News
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Novartis Acquires Spinifex Pharmaceuticals, Inc.
Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline.
Commencement of MED2002 Clinical Trial
Company has received all of the regulatory approvals to begin its pivotal efficacy trial.
Huntingdon Life Sciences and Harlan Laboratories to Become Envigo
The combined company has been created through the integration of Huntingdon Life Sciences and Harlan Laboratories, and three subsidiaries: GFA, NDA Analytics and LSR associates.
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
New IONA® Test Clinical Data Showcased
New clinical data was presented at the World Congress in Fetal Medicine.
NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder
Clinical trial will evaluate the safety and effectiveness of gabapentin enacarbil in treating alcohol use disorder.
CHMP Recommends Granting a Marketing Authorization for Santhera's Raxone®
Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Pfizer Enters into Agreement with GlaxoSmithKline
Agreement with GSK to acquire Nimenrix and Mencevax vaccines.

Events
Parallel Trade – Management St
07 Jul 2015
Parallel Trade – Management St ...
More information
Pharma Serialization: FMD Stra
15 Jul 2015
Pharma Serialization: FMD Stra ...
More information
2nd Clinical Regulatory Medica
15 Jul 2015
2nd Clinical Regulatory Medica ...
More information
CMC Strategy Forum: The Biopha
20 Jul 2015
CMC Strategy Forum: The Biopha ...
More information

ePosters
The Prestwick Chemical Library (R), A Valuable Tool for Screening
1. Prestwick Chemical, 220 Blvd Gonthier d'Andernach, 67400 Strasbourg-Illkirch, FRANCE 2. University of Strasbourg, Therapeuthic Innovation Laboratory, UMR7200 CNRS, Faculty of Pharmacy, 74 route du

The Prestwick Chemical Library® (PCL) is Prestwick’s flagship product dedicated to screening. It is a collection of 1280 molecules comprising 100% approved drugs (FDA, EMEA and other agencies) selected for their high chemical and pharmacological diversity. The PCL was designed to reduce the risk of "low quality" hits and therefore the cost of the initial screening, and appears to be an efficient smart library for hit discovery. The PCL comes with an extended fully-annotated database.
Scale up of Atorvastatin Delayed Release Nanoparticles for Treatment of Hyperlipidemia: Quality by Design (QbD) Approach
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai-400019

The studies describes the implementation of QbD approach in the systematic development of optimized Atorvastatin calcium delayed release nanoparticles (ACDRNPs) employing simple, efficient and cost-effectual technique.
Direct Targets Identification of a Bioactive Compound
Charnwood Molecular, Hybrigenics services SAS

Identifying protein partners of a small bioactive molecule is of great
interest in many aspects of life sciences and specifically in the drug
discovery and development process cycle. It is a support to (i) decipher
the mechanism of action after for example a “High Content” screening,
(ii) study “off-target” effects, (iii) adjust therapeutic indications and
clinical regimens of a drug and (iv) consider drug repositioning.
Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"
UCD Schools of Biomolecular and Biomedical Sciences, UCD Conway Institute, University College Dublin, Dublin, Ireland ////GADEA Grupo Farmacéutico, Parque Tecnologico de Boecillo, Boecillo, Valladolid

3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.
Automated detection and control of controlled substances
Scitegrity Limited

Scitegrity, in conjunction with the Pistoia Alliance and a number of pharmaceutical companies, have developed Controlled Substances Squared to scan large chemical libraries (millions of compounds) and determine whether a compound is considered as controlled in a selected country.
Antioxidant and Free Radicals Scavenging Activity of Biomolecules: Hydroxamic Acids
School of Study in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India

In the present poster attention is focused towards the investigation of antioxidant and free radicals scavenging activity of N-aryl substituted hydroxamic acids by DPPH method which is based on the reduction of alcoholic DPPH solutions in presence of a hydrogen donating antioxidant, hydroxamic acids.
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
1Cisbio Bioassays Codolet, France | 2CRCM, CNRS UMR7258, INSERM U1068, AMU UM105, Institut Paoli-Calmettes, Marseille, France | 3AFMB, UMR7257, Univ. Aix Marseille-CNR

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

Characterization of Proteins and Protein Self Association (Oligomerization) with SEC-MALS
Malvern Instruments Ltd

In this poster, a series of proteins and their oligomers were characterized using SEC-MALS with UV and RI detection. The monomer molecular weights are measured and compared with those from column calibration. The molecular weights of their oligomers are also compared with column calibration and the differences explored.
High Throughput Screening in the European Lead Factory
Pivot Park Screening Centre

This paper describes workflows that have been implemented at the screening centre of the European Lead Factory and presents screening statistics on the first 18 months of operation.
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
(1)Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.
Application Notes
Drug Product Identification Using Handheld Raman
Rigaku Raman Technologies

Handheld Raman spectroscopy is well accepted as a technique for raw material and excipient identification within the pharmaceutical industry. Using the correct Raman excitation wavelength can extend its capabilities into the areas of drug substance and drug product identification.
Cellular Dopamine and Intracellular Calcium Signaling Using the Next Generation HTS Microplate Reader
BMG Labtech

Two cell-based signaling assays from Invitrogen, Fluo-4 Direct™ Calcium Assay and Tango™-bla U2OS GPCR Assay, were performed on the PHERAstar FS HTS instrument. The PHERAstar FS has several unique features that enhance the performance of these assays including direct optic bottom reading, high resolution cell layer scanning, injection at the point of measurement and dual emission detection.
Reaction Optimisation and Large Scale Synthesis
Syrris Ltd

A major benefit of flow chemistry is the ease and consistency of reaction scale up. In a flow reactor, high quality, reproducible mixing, excellent temperature control and superheating are maintained when increasing reaction volume.
Automated Turnkey Solubility and Permeability Assays
Molecular Devices

Millipore Corporation and Molecular Devices have partnered to provide platforms for solubility and permeability screening. The objective is to create automation-compatible 96- and 384-based systems with pre-validated methods, devices and analysis that can be run manually or in conjunction with standard laboratory automation.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters